Sponsors (2)
The bill aims to speed patient access to lower-cost biosimilars and reduce regulatory friction by clarifying roles and expanding remote/MRA-based inspections, but it trades off greater reliance on non‑onsite oversight and new processes that could increase costs, regulatory uncertainty, and safety or transparency risks if not carefully implemented.
Patients with chronic conditions could get faster access to lower-cost biosimilar medicines because the bill encourages expanded use of mutual recognition, remote and risk-based inspections, and quicker resolution of inspection issues.
Hospitals, health systems, manufacturers and taxpayers may see lower costs from more efficient approvals and inspections (reduced travel/on-site burdens, faster procurement savings, and clearer inspection expectations that shorten delays).
Regulatory clarity and FDA accountability would improve: clearer statutory definitions and naming of the implementing authority, public meetings and reports, and steps to boost inspection workforce capacity could centralize responsibility and reduce ambiguity in enforcement.
Relying more on foreign inspections, mutual recognition agreements, and remote assessments could miss on-the-ground problems and raise risks to product quality or patient safety.
Implementing and supporting remote-assessment systems, adapting to new MRA processes, and hiring/retaining inspection staff may impose additional costs on manufacturers, facilities, and the FDA — potentially increasing federal spending or requiring reallocation of taxpayer-funded resources — and oversight gaps could produce costly corrective actions later.
Narrow or technical statutory definitions and greater reliance on guidance/remote tools could create regulatory uncertainty, inadvertently exclude some products or facilities from intended pathways, and reduce transparency for state and local regulators.
Based on analysis of 5 sections of legislative text.
Directs FDA to modernize biosimilar inspection policies: hold a meeting on MRAs, expand remote assessments and alternative tools, and publish a one-year strategic plan.
Introduced December 16, 2025 by Theodore Paul Budd · Last progress December 16, 2025
Directs HHS/FDA to modernize and streamline inspections of biosimilar biological product establishments by holding a public meeting on mutual recognition agreements, increasing use of remote regulatory assessments and alternative inspection tools, and publishing a one-year strategic plan addressing inspection challenges and workforce issues. Sets deadlines for a public meeting and report (within 180 days) and for a strategic plan (within one year) to improve inspection efficiency and communication with biosimilar sponsors.